BUMA PHARMA

BUMA PHARMA has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €38,507 and a net result of €14,746. Equity is growing by ~57.8% per year across the filed fiscal years. Its solvency ranks better than 78% of 22,078 sector peers (NACE 47, fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).